Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.

Hanada R, Bruzelius K, Falkenberg M, Kyhl LE, Møgelmose S, Ravi A, Pinton P, Yoneshima N

Open source

DOI
10.1111/cts.70673
Published
2026 Aug
Container
Clinical and translational science
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/cts.70673,
  title = {Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.},
  author = {Hanada R and Bruzelius K and Falkenberg M and Kyhl LE and Møgelmose S and Ravi A and Pinton P and Yoneshima N},
  year = {2026},
  journal = {Clinical and translational science},
  doi = {10.1111/cts.70673},
  url = {https://doi.org/10.1111/cts.70673}
}

RIS

TY  - JOUR
TI  - Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.
AU  - Hanada R
AU  - Bruzelius K
AU  - Falkenberg M
AU  - Kyhl LE
AU  - Møgelmose S
AU  - Ravi A
AU  - Pinton P
AU  - Yoneshima N
PY  - 2026
JO  - Clinical and translational science
DO  - 10.1111/cts.70673
UR  - https://doi.org/10.1111/cts.70673
ER  - 

APA

R, H., K, B., M, F., LE, K., S, M., A, R., P, P., & N, Y. (2026). Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.. Clinical and translational science. https://doi.org/10.1111/cts.70673

Source records